Guardant Health Stock Current Valuation
| GH Stock | USD 35.10 0.73 2.12% |
Valuation analysis of Guardant Health helps investors to measure Guardant Health's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current Enterprise Value Over EBITDA is estimated to decrease to -7.87. The current Enterprise Value Multiple is estimated to decrease to -7.87. Fundamental drivers impacting Guardant Health's valuation include:
Price Book 55.6696 | Enterprise Value 4.7 B | Enterprise Value Ebitda (5.40) | Price Sales 6.1344 | Enterprise Value Revenue 6.8099 |
Undervalued
Today
Please note that Guardant Health's price fluctuation is very steady at this time. Calculation of the real value of Guardant Health is based on 3 months time horizon. Increasing Guardant Health's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Guardant Health is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Guardant Stock. However, Guardant Health's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 35.1 | Real 42.37 | Target 53.0 | Hype 36.25 | Naive 34.75 |
The intrinsic value of Guardant Health's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Guardant Health's stock price.
Estimating the potential upside or downside of Guardant Health helps investors to forecast how Guardant stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Guardant Health more accurately as focusing exclusively on Guardant Health's fundamentals will not take into account other important factors: Guardant Health Company Current Valuation Analysis
Guardant Health's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Guardant Health Current Valuation | 4.71 B |
Most of Guardant Health's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Guardant Health is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Guardant Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Guardant Health is extremely important. It helps to project a fair market value of Guardant Stock properly, considering its historical fundamentals such as Current Valuation. Since Guardant Health's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Guardant Health's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Guardant Health's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Guardant Health has a Current Valuation of 4.71 B. This is 67.18% lower than that of the Health Care Providers & Services sector and 39.54% lower than that of the Health Care industry. The current valuation for all United States stocks is 71.64% higher than that of the company.
Guardant Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Guardant Health's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Guardant Health could also be used in its relative valuation, which is a method of valuing Guardant Health by comparing valuation metrics of similar companies.Guardant Health is currently under evaluation in current valuation category among its peers.
Guardant Health ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Guardant Health's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Guardant Health's managers, analysts, and investors.Environmental | Governance | Social |
Guardant Fundamentals
| Return On Equity | -6.09 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.74) % | ||||
| Operating Margin | (0.61) % | ||||
| Current Valuation | 4.71 B | ||||
| Shares Outstanding | 123.56 M | ||||
| Shares Owned By Insiders | 4.56 % | ||||
| Shares Owned By Institutions | 95.44 % | ||||
| Number Of Shares Shorted | 10.26 M | ||||
| Price To Earning | (12.01) X | ||||
| Price To Book | 55.67 X | ||||
| Price To Sales | 6.13 X | ||||
| Revenue | 563.95 M | ||||
| Gross Profit | 293.21 M | ||||
| EBITDA | (433.31 M) | ||||
| Net Income | (479.45 M) | ||||
| Cash And Equivalents | 853.69 M | ||||
| Cash Per Share | 8.35 X | ||||
| Total Debt | 1.35 B | ||||
| Debt To Equity | 4.32 % | ||||
| Current Ratio | 6.18 X | ||||
| Book Value Per Share | (0.49) X | ||||
| Cash Flow From Operations | (324.98 M) | ||||
| Short Ratio | 4.56 X | ||||
| Earnings Per Share | (4.28) X | ||||
| Price To Earnings To Growth | (0.66) X | ||||
| Target Price | 43.0 | ||||
| Number Of Employees | 1.77 K | ||||
| Beta | 1.11 | ||||
| Market Capitalization | 4.25 B | ||||
| Total Asset | 1.79 B | ||||
| Retained Earnings | (2.14 B) | ||||
| Working Capital | 1.14 B | ||||
| Current Asset | 219.68 M | ||||
| Current Liabilities | 24.24 M | ||||
| Net Asset | 1.79 B |
About Guardant Health Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Guardant Health's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Guardant Health using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Guardant Health based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Guardant Health Piotroski F Score and Guardant Health Altman Z Score analysis. For more detail on how to invest in Guardant Stock please use our How to Invest in Guardant Health guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Guardant Health. If investors know Guardant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Guardant Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.28) | Revenue Per Share 5.7 | Quarterly Revenue Growth 0.339 | Return On Assets (0.16) | Return On Equity (6.09) |
The market value of Guardant Health is measured differently than its book value, which is the value of Guardant that is recorded on the company's balance sheet. Investors also form their own opinion of Guardant Health's value that differs from its market value or its book value, called intrinsic value, which is Guardant Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Guardant Health's market value can be influenced by many factors that don't directly affect Guardant Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Guardant Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Guardant Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Guardant Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.